BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Immunology

IMBdx Expands Targeted Therapies Agreement after Successful Prostate Cancer Genomic Profiling

The collaboration aims to improve accessibility to targeted therapies for mCRPC patients in international markets outside the US. Traditional tissue biopsi...

June 09, 2023 | News

GeneTex Launches MS Validated PD-L1 Antibody for Immunohistochemistry

The interaction between PD-L1 (CD274/B7-H1) and its receptor programmed death-1 (PD-1) is not only a focus of cancer immunotherapy research but also has ma...

June 08, 2023 | News

Massive Bio and TOI Partner to Revolutionize Cancer Care and Research

Under this visionary collaboration, Massive Bio will support TOI with evaluating the eligibility of patients for TOI's active clinical ...

June 05, 2023 | News

Gilead and Arcus Report Consistent Progression-Free Survival Improvement in Lung Cancer Study

– Objective Response Rate (ORR) Improved in Both Domvanalimab-Containing Study Arms Compared to Zimberelimab Monotherapy – – Resul...

June 05, 2023 | News

National Comprehensive Cancer Network Joins Collaboration to Improve Standards in Cancer Care for Vietnam

The National Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading cancer centers in the United States—today ...

June 01, 2023 | News

Guardant Health's Guardant360® CDx Blood Test Approved by Singapore Health Authority for Advanced Solid Cancers

Guardant360® CDx is a comprehensive genomic profiling blood test that provides critical information to help inform personalized treatment decisi...

May 31, 2023 | News

Sun Pharma and Philogen Sign Exclusive Agreement for NIDLEGY™ Commercialization in Europe, Australia, and New Zealand

Under the terms of the agreement, Sun Pharma will have exclusive rights to commercialise Nidlegy™ for indications of skin cancers in the territories ...

May 31, 2023 | News

Menarini Group's ORSERDU® (Elacestrant) Study Advances in Metastatic Breast Cancer

ORSERDU (elacestrant) was approved by the FDA in January 2023 for advanced or metastatic estrogen receptor (ER)-positive, human epidermal growth factor (...

May 30, 2023 | News

AMP945 and FOLFIRINOX Synergize for Enhanced Pancreatic Cancer Treatment

Amplia's highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic ...

May 30, 2023 | News

Proteomedix Agrees to Issue Labcorp Exclusive License for Proclarix® Blood Test to Detect Prostate Cancer

Proteomedix, a Swiss diagnostics company committed to advancing prostate cancer care, announced today that it entered into an agreement for Labcorp, a...

May 22, 2023 | News

Discovery Life Sciences Joins Akoya Biosciences' Global Network to Boost Immuno-Oncology Research

With this qualification, Discovery gains access to Akoya's PhenoImager® HT workflows, which can provide insights into the tumor microenvironment (...

May 19, 2023 | News

Asieris and UroViu Strengthen Partnership for Bladder Cancer Diagnosis and Treatment Platform

Under the agreement, Asieris Pharmaceuticals will use this patented technology in combination with specific optical imaging agents to conduct research on t...

May 19, 2023 | News

Boan Biotech's BA1202 Approved for Clinical Trial

Boan Biotech announced today that its BA1202, a CEACAM5 (CEA)/CD3 bispecific antibody, has been approved for a clinical trial by the Center for Drug Evalua...

May 17, 2023 | News

Hummingbird Bioscience, Merck to Evaluate HMBD-001 in Lung Carcinoma

Hummingbird Bioscience enters a clinical trial collaboration and supply agreement with Merck to evaluate HMBD-001, a potentially best-in-class anti-HER3 ...

May 16, 2023 | News

Stay Connected